Immune activation and IL‐12 production during acute/early HIV infection in the absence and presence of highly active, antiretroviral therapy

Suppressed IL‐12 production and maladaptive immune activation, both of which are ameliorated by successful highly active antiretroviral therapy (HAART), are thought to play important roles in the immunopathogenesis of chronic HIV infection. Despite the important effects of the immunological and virological events of early HIV infection on subsequent disease progression, IL‐12 production and immune activation in early infection remain under‐defined. To quantify IL‐12 production and immune activation during acute/early HIV infection, in the presence and absence of HAART, we performed a prospective, longitudinal study of participants in the Baltimore site of the Acute Infection and Early Disease Research Program, with cross‐sectional comparison to healthy control subjects. PBMC cytokine productive capacity and plasma immune activation markers [soluble CD8 (sCD8), sCD4, granzyme B, neopterin, β2‐microglobulin, sIL‐2R, sTNFRI, sTNFRII, and IL‐12p70] were quantified by ELISA. Notably, PBMC from patients with acute/early HIV infection exhibited in vivo IL‐12p70 production along with increased, maximal in vitro IL‐12 production. Further, despite evidence from plasma markers of generalized immune activation, no elevation in plasma levels of sCD4 was observed, suggesting relative blunting of in vivo CD4+ T cell activation from the beginning of HIV infection. Finally, despite successful virological responses to HAART, heightened in vivo CD8+ T cell activation, IL‐12 production, and IFN activity were sustained for at least 6 months during primary HIV infection. These data underscore the need for comparative mechanistic analysis of the immunobiology of early and chronic HIV infection.

[1]  S. Karim,et al.  Relationship between levels of inflammatory cytokines in the genital tract and CD4+ cell counts in women with acute HIV-1 infection. , 2008, The Journal of infectious diseases.

[2]  A. Sönnerborg,et al.  Early immune activation in gut-associated and peripheral lymphoid tissue during acute HIV infection , 2007, AIDS.

[3]  J. Brenchley,et al.  Microbial translocation is a cause of systemic immune activation in chronic HIV infection , 2006, Retrovirology.

[4]  J. Löwer,et al.  Neopterin levels during the early phase of human immunodeficiency virus, hepatitis C virus, or hepatitis B virus infection , 2006, Transfusion.

[5]  David R Bangsberg,et al.  Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. , 2006, JAMA.

[6]  B. Custer,et al.  Elevations in IL-10, TNF-α, and IFN-γfrom the Earliest Point of HIV Type 1 Infection , 2006 .

[7]  P. Krogstad,et al.  Immunological response to highly active antiretroviral therapy in children with clinically stable HIV-1 infection. , 2005, The Journal of infectious diseases.

[8]  P. Lebon,et al.  Type I interferon production is profoundly and transiently impaired in primary HIV-1 infection. , 2005, The Journal of infectious diseases.

[9]  Geoffrey H. Holm,et al.  Distinct Mechanisms of CD4+ and CD8+ T-Cell Activation and Bystander Apoptosis Induced by Human Immunodeficiency Virus Type 1 Virions , 2005, Journal of Virology.

[10]  G. Trinchieri,et al.  A type I interferon autocrine–paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells , 2005, The Journal of experimental medicine.

[11]  J. Benito,et al.  Differential Upregulation of CD38 on Different T-Cell Subsets May Influence the Ability to Reconstitute CD4+ T Cells Under Successful Highly Active Antiretroviral Therapy , 2005, Journal of acquired immune deficiency syndromes.

[12]  Dietmar Fuchs,et al.  Neopterin in HIV-1 infection. , 2005, Molecular immunology.

[13]  Peter Hunt,et al.  Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. , 2004, Blood.

[14]  J. Benito,et al.  CD38 expression on CD8 T lymphocytes as a marker of residual virus replication in chronically HIV-infected patients receiving antiretroviral therapy. , 2004, AIDS research and human retroviruses.

[15]  Tao Dong,et al.  Immune Activation and CD8+ T-Cell Differentiation towards Senescence in HIV-1 Infection , 2004, PLoS biology.

[16]  J. O’Shea,et al.  The biology of IL-12: coordinating innate and adaptive immune responses. , 2003, Cytokine & growth factor reviews.

[17]  F. Miedema,et al.  Persistent immune activation in HIV-1 infection is associated with progression to AIDS , 2003, AIDS.

[18]  D. Fuchs,et al.  Monocyte‐derived dendritic cells release neopterin , 2002, Journal of leukocyte biology.

[19]  W. Moss,et al.  Functional and Phenotypic Changes in Circulating Lymphocytes from Hospitalized Zambian Children with Measles , 2002, Clinical and Vaccine Immunology.

[20]  H. Whittle,et al.  Natural measles causes prolonged suppression of interleukin-12 production. , 2001, The Journal of infectious diseases.

[21]  G. Trinchieri,et al.  Type I interferons and IL‐12: convergence and cross‐regulation among mediators of cellular immunity , 2001, European journal of immunology.

[22]  J. McCune,et al.  The dynamics of CD4+ T-cell depletion in HIV disease , 2001, Nature.

[23]  R. Siliciano,et al.  Biphasic decay of latently infected CD4+ T cells in acute human immunodeficiency virus type 1 infection. , 2000, The Journal of infectious diseases.

[24]  H. Schuitemaker,et al.  T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock , 2000, Nature Immunology.

[25]  E. Rosenberg,et al.  Immune control of HIV-1 after early treatment of acute infection , 2000, Nature.

[26]  M. Lederman,et al.  `Modeling' relationships among HIV-1 replication, immune activation and CD4+ T-cell losses using adjusted correlative analyses , 2000, AIDS.

[27]  R H Lyles,et al.  Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. , 2000, The Journal of infectious diseases.

[28]  G. Trinchieri,et al.  The interleukin-12-mediated pathway of immune events is dysfunctional in human immunodeficiency virus-infected individuals. , 1999, Blood.

[29]  G A Satten,et al.  New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. , 1998, JAMA.

[30]  Lawrence Corey,et al.  Biological and Virologic Characteristics of Primary HIV Infection , 1998, Annals of Internal Medicine.

[31]  S. Buchbinder,et al.  CD40 ligand and IFN‐γ synergistically restore IL‐12 production in HIV‐infected patients , 1998 .

[32]  M. Daucher,et al.  The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[33]  A. Sher,et al.  Molecular analysis of decreased interleukin-12 production in persons infected with human immunodeficiency virus. , 1996, The Journal of infectious diseases.

[34]  C. Sabin,et al.  Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients. , 1996, AIDS.

[35]  J. Berzofsky,et al.  In vitro restoration of T cell immune function in human immunodeficiency virus-positive persons: effects of interleukin (IL)-12 and anti-IL-10. , 1996, The Journal of infectious diseases.

[36]  A. Lazzarin,et al.  Cytokines and soluble receptor changes in the transition from primary to early chronic HIV type 1 infection. , 1996, AIDS research and human retroviruses.

[37]  T. Idziorek,et al.  T helper type 1/T helper type 2 cytokines and T cell death: preventive effect of interleukin 12 on activation-induced and CD95 (FAS/APO-1)- mediated apoptosis of CD4+ T cells from human immunodeficiency virus- infected persons , 1995, The Journal of experimental medicine.

[38]  H. Ullum,et al.  Defective natural immunity: an early manifestation of human immunodeficiency virus infection , 1995, The Journal of experimental medicine.

[39]  G. Trinchieri,et al.  Priming for high interferon-gamma production induced by interleukin-12 in both CD4+ and CD8+ T cell clones from HIV-infected patients. , 1995, The Journal of clinical investigation.

[40]  A. Sher,et al.  HIV infection suppresses type 1 lymphokine and IL-12 responses to Toxoplasma gondii but fails to inhibit the synthesis of other parasite-induced monokines. , 1995, Journal of immunology.

[41]  K. Nakahara,et al.  Increased levels of soluble CD8 and CD4 in patients with infectious mononucleosis , 1995, British journal of haematology.

[42]  G. Trinchieri,et al.  Impaired interleukin 12 production in human immunodeficiency virus- infected patients , 1994, The Journal of experimental medicine.

[43]  S. Zolla-Pazner,et al.  Delayed-type hypersensitivity skin tests are an independent predictor of human immunodeficiency virus disease progression. Department of Veterans Affairs Cooperative Study Group. , 1994, The Journal of infectious diseases.

[44]  J. Berzofsky,et al.  Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. , 1993, Science.

[45]  R. Raiteri,et al.  Cytokine network and acute primary HIV‐1 infection , 1993, AIDS.

[46]  D. Griffin,et al.  Differential CD4 T cell activation in measles. , 1993, The Journal of infectious diseases.

[47]  E. Borden,et al.  Effects of Interferons β or γ on Neopterin Biosynthesis and Tryptophan Degradation by Human Alveolar Macrophages In Vitro: Synergy with Lipopolysaccharide , 1992 .

[48]  G. Prignano,et al.  Behaviour of several 'progression markers' during the HIV-Ab seroconversion period. Comparison with later stages. , 1992, Journal of biological regulators and homeostatic agents.

[49]  I. Frank,et al.  Natural killer (NK) cell stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients , 1992, The Journal of experimental medicine.

[50]  O. Strannegard,et al.  Interferon-alpha and tumor necrosis factor-alpha in serum of patients in various stages of HIV-1 infection. , 1991, AIDS research and human retroviruses.

[51]  J. Wasserman,et al.  Immunological changes in primary HIV‐1 infection , 1990, AIDS.

[52]  M. Clerici,et al.  Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging. , 1989, The Journal of clinical investigation.

[53]  T. Waldmann,et al.  Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. , 1985, The New England journal of medicine.

[54]  J. McArthur,et al.  Interferon-beta therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin-10 production. , 2002, Annals of neurology.

[55]  M. Goldman New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes , 1999 .

[56]  G. Trinchieri Interleukin-12: a cytokine at the interface of inflammation and immunity. , 1998, Advances in immunology.

[57]  A. Sinicco,et al.  Serum cytokine profiles in acute primary HIV-1 infection and in infectious mononucleosis. , 1996, Clinical immunology and immunopathology.

[58]  E. Maggi,et al.  Reduced production of interleukin 2 and interferongamma and enhanced helper activity for IgG synthesis by cloned CD4+ T cells from patients with AIDS , 1987, European journal of immunology.

[59]  J. Margolick,et al.  Natural History of Human Immunodeficiency Virus Type 1 Viremia after Seroconversion and Proximal to AIDS in a Large Cohort of Homosexual Men , 2022 .